US Stock MarketDetailed Quotes
RPRX Royalty Pharma
- 28.330
- +0.260+0.93%
Trading May 15 11:38 ET
12.78BMarket Cap15.92P/E (TTM)
28.375High28.115Low629.74KVolume28.220Open28.070Pre Close17.79MTurnover0.16%Turnover Ratio11.20P/E (Static)450.98MShares33.91652wk High1.97P/B11.00BFloat Cap25.54352wk Low0.81Dividend TTM388.11MShs Float52.434Historical High2.86%Div YieldTTM0.93%Amplitude25.543Historical Low28.254Avg Price1Lot Size
Royalty Pharma Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -35.71%664.64M | 39.36%2.99B | 35.57%772.63M | 6.44%573.52M | 5.72%607.82M | 124.62%1.03B | 6.27%2.14B | 16.32%569.93M | 14.70%538.83M | 8.13%574.95M |
| Net income from continuing operations | -100.84%-4.27M | 638.96%1.7B | 217.63%717.59M | -44.61%122.08M | -28.53%351.34M | 297.47%509.09M | -81.46%230.06M | -1,236.61%-610.03M | -0.62%220.41M | -39.06%491.6M |
| Operating gains losses | 13.00%-605.13M | -17.05%-2.54B | -55.34%-809.32M | 27.50%-381.1M | -1.03%-656.35M | -46.20%-695.57M | -8.08%-2.17B | -11.41%-521M | -5.91%-525.64M | -13.04%-649.66M |
| Depreciation and amortization | ---- | --0 | --0 | --0 | ---- | ---- | -75.34%5.67M | --0 | --0 | --0 |
| Other non cash items | -35.15%752.35M | 30.43%3.24B | 19.00%769.85M | 7.93%714.03M | 7.29%598.84M | 87.23%1.16B | 8.59%2.49B | 11.76%646.94M | 4.39%661.56M | 8.86%558.15M |
| Change In working capital | 31.62%-29.5M | -83.52%5.38M | 92.04%47.91M | -19.51%-37.02M | -52.00%37.63M | -8.62%-43.14M | 300.11%32.66M | -45.81%24.95M | 50.80%-30.98M | 133.50%78.41M |
| -Change in receivables | 114.83%178K | -96.64%1.07M | 172.18%1.27M | -632.74%-2.69M | -87.90%3.69M | -147.98%-1.2M | 208.82%31.71M | -133.78%-1.75M | 101.76%504K | 729.10%30.46M |
| -Change in payables and accrued expense | -1.16%-42.7M | 400.96%3.76M | 33.32%43.67M | -2.04%-37.78M | -13.77%40.08M | 2.86%-42.21M | -111.38%-1.25M | -14.95%32.76M | -35.15%-37.03M | 36.99%46.48M |
| -Change in other current assets | 4,637.45%13.03M | -74.57%559K | 149.07%2.97M | -37.89%3.44M | -517.22%-6.13M | -77.86%275K | 18.36%2.2M | -359.87%-6.06M | 232.71%5.54M | -16.72%1.47M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -35.71%664.64M | 39.36%2.99B | 35.57%772.63M | 6.44%573.52M | 5.72%607.82M | 124.62%1.03B | 6.27%2.14B | 16.32%569.93M | 14.70%538.83M | 8.13%574.95M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 84.49%-86.65M | -101.35%-2.07B | -341.16%-1B | 68.38%-450.66M | -110.20%-63.43M | -5,102.47%-558.53M | 44.96%-1.03B | 175.18%414.74M | -68.56%-1.43B | -123.92%-30.18M |
| Net business purchase and sale | -94.78%-6.97M | -26.74%-12.54M | ---1.99M | 41.81%-3.98M | ---2.99M | -17.34%-3.58M | 71.61%-9.9M | --0 | 37.15%-6.85M | --0 |
| Net investment purchase and sale | 85.34%-84.64M | -104.97%-2.09B | -341.31%-1B | 68.19%-451.13M | -100.30%-60.45M | -4,161.30%-577.31M | 43.90%-1.02B | 176.08%414.74M | -69.94%-1.42B | -119.73%-30.18M |
| Net other investing changes | ---- | ---14.44M | ---2.04M | --0 | --0 | ---12.4M | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 84.49%-86.65M | -101.35%-2.07B | -341.16%-1B | 68.38%-450.66M | -110.20%-63.43M | -5,102.47%-558.53M | 44.96%-1.03B | 175.18%414.74M | -68.56%-1.43B | -123.92%-30.18M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -0.77%-212M | -127.42%-2.15B | 12.67%-231.89M | -490.86%-1.36B | -52.02%-347M | 4.79%-210.37M | -345.35%-944.86M | -34.07%-265.55M | -122.25%-230.09M | -1.71%-228.25M |
| Net issuance payments of debt | ---- | ---1B | --0 | ---- | ---- | ---- | --0 | --0 | ---- | ---- |
| Net common stock issuance | ---- | ---304.76M | ---30.2M | ---140.12M | ---- | ---- | --0 | --0 | --0 | ---- |
| Cash dividends paid | -5.84%-93.81M | -7.50%-358.33M | -6.10%-89.34M | -7.09%-89.75M | -9.10%-90.61M | -7.74%-88.63M | -16.88%-333.32M | -14.40%-84.2M | -14.78%-83.81M | -14.42%-83.05M |
| Net other financing activities | 2.91%-118.19M | 20.58%-485.67M | 38.04%-112.36M | 11.39%-129.62M | 16.02%-121.95M | 12.23%-121.74M | -1.54%-611.53M | -45.70%-181.35M | 11.48%-146.28M | 4.37%-145.21M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -0.77%-212M | -127.42%-2.15B | 12.67%-231.89M | -490.86%-1.36B | -52.02%-347M | 4.79%-210.37M | -345.35%-944.86M | -34.07%-265.55M | -122.25%-230.09M | -1.71%-228.25M |
| Net cash flow | ||||||||||
| Beginning cash position | -72.12%477.01M | 11.01%1.71B | -5.56%936.45M | 3.09%2.17B | 10.28%1.98B | 11.01%1.71B | 52.78%1.54B | -44.93%991.63M | 84.55%2.11B | 152.75%1.79B |
| Current changes in cash | 38.14%365.99M | -827.00%-1.23B | -163.89%-459.44M | -10.77%-1.24B | -37.64%197.39M | 5.78%264.94M | -68.12%169.7M | 376.84%719.12M | -269.53%-1.12B | -26.98%316.52M |
| End cash Position | -57.33%843M | -72.12%477.01M | -72.12%477.01M | -5.56%936.45M | 3.09%2.17B | 10.28%1.98B | 11.01%1.71B | 11.01%1.71B | -44.93%991.63M | 84.55%2.11B |
| Free cash flow | -35.71%664.64M | 39.36%2.99B | 35.57%772.63M | 6.44%573.52M | 5.72%607.82M | 124.62%1.03B | 6.27%2.14B | 16.32%569.93M | 14.70%538.83M | 8.13%574.95M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg